Information Provided By: 
Fly News Breaks for June 30, 2016
TSRO
Jun 30, 2016 | 08:14 EDT
Leerink analyst Seamus Fernandez raised his price target for TESARO to $95 from $65 saying top-line results from its Phase 3 NOVA trial of niraparib, a PARP inhibitor, in ovarian cancer maintenance treatment is as close to a "best case scenario" as it gets, adding that hitting the progression free survival on the overall germline BRCA mutation negative population is an "unexpected upside." Fernandez reiterates an Outperform rating on the shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
